$VNDA
Vanda Pharmaceuticals Inc.

2021 Q2 Form 10-Q Financial Statement

#000134717821000028 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $67.90M $62.21M
YoY Change 9.15% 5.33%
Cost Of Revenue $6.566M $5.850M
YoY Change 12.24% -8.13%
Gross Profit $61.33M $55.99M
YoY Change 9.54% 7.03%
Gross Profit Margin 90.33% 90.01%
Selling, General & Admin $28.35M $33.92M
YoY Change -16.42% 7.78%
% of Gross Profit 46.22% 60.58%
Research & Development $20.25M $12.90M
YoY Change 56.92% 17.84%
% of Gross Profit 33.01% 23.04%
Depreciation & Amortization $727.0K $600.0K
YoY Change 21.17% -25.0%
% of Gross Profit 1.19% 1.07%
Operating Expenses $48.60M $46.82M
YoY Change 3.79% 10.38%
Operating Profit $12.37M $9.171M
YoY Change 34.87% -7.32%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $235.0K $1.920M
YoY Change -87.76% 16.36%
Pretax Income $12.60M $11.09M
YoY Change 13.66% -3.94%
Income Tax $3.000M $2.400M
% Of Pretax Income 23.8% 21.64%
Net Earnings $9.653M $8.714M
YoY Change 10.78% -24.4%
Net Earnings / Revenue 14.22% 14.01%
Basic Earnings Per Share $0.17 $0.16
Diluted Earnings Per Share $0.17 $0.16
COMMON SHARES
Basic Shares Outstanding 55.58M shares 54.50M shares
Diluted Shares Outstanding 56.90M shares 55.08M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $396.5M $339.8M
YoY Change 16.67% 21.3%
Cash & Equivalents $57.24M $95.31M
Short-Term Investments $339.3M $244.5M
Other Short-Term Assets $12.01M $15.00M
YoY Change -19.91% 40.19%
Inventory $1.055M $1.384M
Prepaid Expenses
Receivables $37.09M $24.59M
Other Receivables $0.00 $0.00
Total Short-Term Assets $446.7M $380.9M
YoY Change 17.27% 20.6%
LONG-TERM ASSETS
Property, Plant & Equipment $3.631M $3.744M
YoY Change -3.02% -11.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $86.64M $89.10M
YoY Change -2.76% 1925.0%
Total Long-Term Assets $121.0M $125.8M
YoY Change -3.8% 121.89%
TOTAL ASSETS
Total Short-Term Assets $446.7M $380.9M
Total Long-Term Assets $121.0M $125.8M
Total Assets $567.6M $506.6M
YoY Change 12.04% 36.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.918M $5.400M
YoY Change 9.59% -5.26%
Accrued Expenses $65.72M $23.00M
YoY Change 185.74% -59.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.99M $61.59M
YoY Change 16.88% -1.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.696M $1.735M
YoY Change 113.03% 685.07%
Total Long-Term Liabilities $3.696M $1.735M
YoY Change 113.03% 685.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.99M $61.59M
Total Long-Term Liabilities $3.696M $1.735M
Total Liabilities $86.43M $75.05M
YoY Change 15.16% -0.98%
SHAREHOLDERS EQUITY
Retained Earnings -$179.0M -$211.5M
YoY Change -15.34% -34.99%
Common Stock $660.1M $642.5M
YoY Change 2.75% 3.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $481.2M $431.6M
YoY Change
Total Liabilities & Shareholders Equity $567.6M $506.6M
YoY Change 12.04% 36.01%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $9.653M $8.714M
YoY Change 10.78% -24.4%
Depreciation, Depletion And Amortization $727.0K $600.0K
YoY Change 21.17% -25.0%
Cash From Operating Activities $19.01M $24.00M
YoY Change -20.79% 16.5%
INVESTING ACTIVITIES
Capital Expenditures -$328.0K -$200.0K
YoY Change 64.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities -$33.88M $2.900M
YoY Change -1268.34% -125.44%
Cash From Investing Activities -$34.21M $2.700M
YoY Change -1367.04% -123.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 338.0K 3.600M
YoY Change -90.61% 5.88%
NET CHANGE
Cash From Operating Activities 19.01M 24.00M
Cash From Investing Activities -34.21M 2.700M
Cash From Financing Activities 338.0K 3.600M
Net Change In Cash -14.86M 30.30M
YoY Change -149.05% 146.34%
FREE CASH FLOW
Cash From Operating Activities $19.01M $24.00M
Capital Expenditures -$328.0K -$200.0K
Free Cash Flow $19.34M $24.20M
YoY Change -20.09% 15.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34186
dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300 E
dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
dei City Area Code
CityAreaCode
202
dei Local Phone Number
LocalPhoneNumber
734-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
VNDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55638166 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57242000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
339251000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306709000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37090000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30036000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
1055000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12014000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10089000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
446652000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
409145000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3631000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4136000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9898000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10459000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20820000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21559000 USD
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
78641000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81516000 USD
CY2021Q2 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
8003000 USD
CY2020Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
6641000 USD
CY2021Q2 us-gaap Assets
Assets
567645000 USD
CY2020Q4 us-gaap Assets
Assets
533456000 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31788000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q2 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
40201000 USD
CY2020Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
34427000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
71989000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65936000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10740000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11497000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3696000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2757000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
86425000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
80190000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55627666 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55627666 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54865092 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54865092 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
660086000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
650300000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
103000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179025000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197328000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
481220000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
567645000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533456000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67899000 USD
CY2021Q2 us-gaap Revenues
Revenues
67899000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62207000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130568000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120207000 USD
CY2020Q2 us-gaap Revenues
Revenues
62207000 USD
us-gaap Revenues
Revenues
130568000 USD
us-gaap Revenues
Revenues
120207000 USD
CY2021Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6566000 USD
CY2020Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
5847000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
12596000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
11054000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20248000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12903000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36379000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28430000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28347000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33917000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58144000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
70938000 USD
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
369000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
369000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
55530000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
53036000 USD
us-gaap Costs And Expenses
CostsAndExpenses
107858000 USD
us-gaap Costs And Expenses
CostsAndExpenses
111161000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
12369000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9171000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
22710000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
9046000 USD
CY2021Q2 us-gaap Other Income
OtherIncome
235000 USD
CY2020Q2 us-gaap Other Income
OtherIncome
1918000 USD
us-gaap Other Income
OtherIncome
322000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
12604000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
11089000 USD
us-gaap Other Income
OtherIncome
3284000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
23032000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
12330000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2951000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2375000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4729000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3130000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
us-gaap Net Income Loss
NetIncomeLoss
18303000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55582916 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54501308 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55365558 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54153812 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56903340 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55081397 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56705419 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54975771 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
us-gaap Net Income Loss
NetIncomeLoss
18303000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
16000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
10000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-31000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-3000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-136000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-252000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-135000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
453000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-31000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-57000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-30000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
103000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-89000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-136000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
347000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9564000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8529000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
18167000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9547000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1849000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3909000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
467627000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
289000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3740000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-89000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
481220000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
479000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000 USD
us-gaap Depreciation
Depreciation
688000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
532000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
416386000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3600000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3069000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
431584000 USD
us-gaap Net Income Loss
NetIncomeLoss
18303000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
us-gaap Depreciation
Depreciation
694000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7649000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7013000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1016000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
420000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
12000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
229000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1672000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1554000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
591000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2906000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2019000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-666000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-695000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7064000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1366000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
888000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
883000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
5351000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
1414000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28210000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2138000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23099000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
428000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
583000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
197352000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
151124000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
163670000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
174739000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34110000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23032000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4079000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2138000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4079000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-29000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3791000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50233000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57822000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95883000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57242000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95305000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57822000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95883000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67899000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62207000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130568000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120207000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
339181000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
117000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339251000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306504000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
216000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306709000 USD
CY2021Q2 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4359000 USD
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
348249000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306709000 USD
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
20000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
66000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1035000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1214000 USD
CY2020Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4045000 USD
CY2020Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
744000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
1055000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q2 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
1261000 USD
CY2021Q2 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
967000 USD
CY2020Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
302000 USD
CY2021Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
6587000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5091000 USD
CY2021Q2 vnda Inventory
Inventory
7642000 USD
CY2020Q4 vnda Inventory
Inventory
6371000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2142000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2117000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 USD
CY2021Q2 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
10321000 USD
CY2020Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
6173000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6932000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5052000 USD
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5918000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5817000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4008000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10951000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q2 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2020Q4 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2117000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1049000 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31788000 USD
vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
50000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
81000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
53000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
158000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
103000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.65
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2100000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4100000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3740000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3069000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7649000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7013000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0128
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000000.0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3100000 USD
CY2021Q2 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
300000 USD
CY2020Q2 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
700000 USD
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
100000 USD
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1100000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
us-gaap Net Income Loss
NetIncomeLoss
18303000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55582916 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54501308 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55365558 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54153812 shares
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1320424 shares
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
580089 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1339861 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
821959 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56903340 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55081397 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56705419 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54975771 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2212724 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3813824 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2174917 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3454524 shares

Files In Submission

Name View Source Status
0001347178-21-000028-index-headers.html Edgar Link pending
0001347178-21-000028-index.html Edgar Link pending
0001347178-21-000028.txt Edgar Link pending
0001347178-21-000028-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20210630.htm Edgar Link pending
vnda-20210630.xsd Edgar Link pending
vnda-20210630_cal.xml Edgar Link unprocessable
vnda-20210630_def.xml Edgar Link unprocessable
vnda-20210630_htm.xml Edgar Link completed
vnda-20210630_lab.xml Edgar Link unprocessable
vnda-20210630_pre.xml Edgar Link unprocessable
vndaex311630202110q.htm Edgar Link pending
vndaex312630202110q.htm Edgar Link pending
vndaex321630202110q.htm Edgar Link pending